文献速递系统性红斑狼疮其他结缔组织病

贝利尤单抗妊娠期治疗的真实世界妊娠结局报告

Pregnancy outcomes in patients treated with belimumab: Report from real-world experience.
PubMed 文献 · Semin Arthritis Rheum · 2021-06-24

结果显示11例活产(84.6%),1例新生儿脐炎经抗生素治愈,无胎儿白细胞减少、淋巴细胞减少、中性粒细胞减少或血小板减少,无胎儿畸形。结论认为妊娠期暴露于贝利尤单抗未增加胎儿畸形或严重感染风险,但仍需谨慎监测并积累更多数据。

要点

  • 13次妊娠中11例活产(84.6%),1例新生儿脐炎经抗生素治愈。
  • 无胎儿白细胞减少、淋巴细胞减少、中性粒细胞减少或血小板减少,无胎儿畸形。
  • 6例有复发性流产史患者中4例活产。

核心结论

  • 妊娠期暴露于贝利尤单抗未增加胎儿畸形或严重感染风险,但仍需谨慎监测并积累更多数据验证安全性。

主要发现

  • 中位年龄38岁(四分位距32-41岁),46.2%有复发性妊娠丢失史,贝利尤单抗(每剂400 mg)中位治疗疗程数为2。
  • 13次妊娠中11例活产(84.6%),1例胎儿发生脐炎经抗生素治疗后恢复良好。
  • 新生儿出生后数日内未观察到白细胞减少、淋巴细胞减少、中性粒细胞减少或血小板减少,本系列未发现胎儿畸形。
  • 6例有复发性妊娠丢失史的患者中4例活产。

临床怎么用

  • 妊娠期使用贝利尤单抗需谨慎监测,当前数据提示未增加胎儿畸形或严重感染风险,但需更多数据验证。

局限性

  • 回顾性设计、样本量小(13次妊娠)、单中心经验,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the neonatal and maternal outcomes of patients treated with belimumab during pregnancy. MATERIALS AND METHODS: We retrospectively collected patients who were treated with belimumab during pregnancy from January 2018 to October 2020 in a tertiary referral hospital in Taiwan. All patients had clinical and serological features of systemic lupus erythematosus or antiphospholipid syndrome and had been treated accordingly. The patients' medical and obstetric history, obstetric complications and fetal outcomes were collected by chart review. RESULTS: A total of 13 pregnancies in 13 patients were included. The median age was 38 years (interquartile range 32-41 years), 46.2% had a history of recurrent pregnancy loss, and the median number of treatment courses with belimumab (400 mg per dose) was two. There were 11 live births (84.6%, 11 of 13). One episode of omphalitis was noted in one fetus, who recovered well with antibiotic treatment. No fetus had leukopenia, lymphopenia, neutropenia, or thrombocytopenia in the days after birth. No fetal anomalies were found in this series. Among the six patients with a past history of recurrent pregnancy loss, four had live births. CONCLUSION: This study provides new evidence for the use of belimumab in pregnant patients. No increase in the risk of fetal anomalies or severe infection was noted in the patients who were exposed to belimumab during pregnancy. Cautious monitoring is necessary if belimumab is used in pregnant patients, and more data are still needed to validate its safety.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kao JH, Lan TY, Lu CH, et al. Pregnancy outcomes in patients treated with belimumab: Report from real-world experience. Semin Arthritis Rheum. 2021. PMID: 34403811. doi:10.1016/j.semarthrit.2021.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。